Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

Phase 2 Unknown 60 enrolled Anhui Provincial Hospital

RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.

Timeline

Start: 2017-10-01
Primary completion: 2019-10-01
Completion: 2019-12-01

Outcome

Missed primary endpoint

paper median PFS: 3.88 (95% CI: 1.72-6.03) months vs. 3.98 (95% CI: 1.06-6.90) months, P=0.546 PMID 35280426 ↗

Publications

Yan Y, Li H, Wu S, Wang G, Luo H, Niu J, Cao L, Hu X, Xu H, Jia W, Sun Y, Yao Y, Chen W, Ke L, Hu B, Ji C, Sun Y, Chen J, Li M, He Y. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study. Ann Transl Med. 2022 Feb;10(4):205. doi: 10.21037/atm-22-546.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	500 mg	—
Background	Docetaxel	Small molecule	60 mg/m2	—

Indications

No indication recorded.